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 ORIGINAL ARTICLE: CLINICAL 
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 Introduction 
 In the last few years, comprehensive geriatric assessment 
(CGA) has been recognized as an essential tool for clinicians 
who manage elderly people aff ected by aggressive diseases [1]. 
Th e defi nition of elderly is still a matter of debate in 
oncology. In patients with lymphoma, the age limit more 
frequently used to discriminate between younger and older 
patients is 65 years [2]. 
 It is no longer acceptable to exclude patients from inten-
sive treatment with curative intent only on the basis of 
chronological age. Aging is highly individualized in terms of 
life expectancy, functional reserve and social support, and 
treatment plans need to account for this diversity that can be 
better evaluated by a multidimensional approach [3]. 
 Diff use large B-cell lymphoma (DLBCL) represents a 
typical example of neoplastic disease that can be cured with 
an aggressive program. Th e majority of patients with DLBCL 
are over the age of 60 years, and the steady improvement of 
life expectancy will probably further increase their number in 
the future [2]. Th erefore, trying to improve the survival of this 
category of patients represents one of the major challenges 
for hematologists. CGA proved to be an eff ective method to 
identify elderly patients with DLBCL able to tolerate intensive 
treatment with curative intent, achieving an outcome similar 
to that of younger patients [4]. However, about one-half of 
elderly patients cannot benefi t from a curative approach, 
and their prognosis is still very poor, independent of treat-
ment received. 
 Although broad agreement exists among oncologists 
on the diff erent aspects of geriatric assessment and the 
instruments to use for evaluating the performance of elderly 
 Abstract 
 We performed a multicenter study to validate the concept that 
a simple comprehensive geriatric assessment (CGA) can identify 
elderly, non-fi t patients with diff use large B-cell lymphoma 
(DLBCL) in whom curative treatment is not better then palliation, 
and to analyze potential benefi ts of treatment modulation after 
further subdividing the non-fi t category by CGA criteria. One 
hundred and seventy-three patients aged    69 treated with 
curative or palliative intent by clinical judgement only were 
grouped according to CGA into fi t (46%), unfi t (16%) and frail 
(38%) categories. Two-year overall survival (OS) was signifi cantly 
better in fi t than in non-fi t patients (84% vs. 47%;  p    0.0001). 
Survival in unfi t and frail patients was not signifi cantly diff erent. 
Curative treatment slightly improved 2-year OS in unfi t (75% vs. 
45%) but not in frail patients (44% vs. 39%). CGA was confi rmed 
as very effi  cient in identifying elderly patients with DLBCL who 
can benefi t from a curative approach. Further eff orts are needed 
to better tailor therapies in non-fi t patients. 
 Keywords:  Lymphoma and Hodgkin disease ,  chemotherapeutic 
approaches ,  immunotherapy 
922 A. Tucci et al. 
people, the categories of elderly patients that need to be 
identifi ed are still debated, and interpretation of the results 
of CGA tests has not yet been standardized. In particular, 
since new and very eff ective treatments with a better toler-
ability profi le such as anti-CD20 monoclonal antibodies 
have become available, the attempt to defi ne non-fi t patients 
according to the extent of their limitations could help clini-
cians to better tailor treatment in an attempt to improve the 
effi  cacy of therapies in this patient category. 
 Th erefore the Italian Lymphoma Foundation (FIL) 
launched a multicenter prospective study to verify our previ-
ous results in a broader population of patients with DLBCL 
with the same clinical characteristics, and to assess the 
potential usefulness of a CGA that further divides non-fi t 
patients into two diff erent levels according to the severity of 
their unfi tness. 
 Patients and methods 
 All consecutive patients with DLBCL aged more than 69 
years seen in 13 hematology departments of the FIL were 
recorded during 1 year. CGA was performed during stag-
ing procedures, after written informed consent, through 
application of the following instruments: (1) age    80 years; 
(2) comorbidity score according to the Cumulative Illness 
Rating Score for Geriatrics (CIRS-G) [5] and evaluated in all 
organs/systems as follows: no problem   0, mild problem 
(may require treatment)   1, moderate disability or morbid-
ity (treatment required)   2, severe, constant, signifi cant 
disability/ “ uncontrollable ” chronic problems   3, extremely 
severe disability, immediate treatment required/end organ 
failure/severe impairment in function   4; (3) activity of daily 
living (ADL), that is, loss in any activity, including bathing, 
dressing, toileting, transferring, feeding and continence [6]; 
(4) instrumental activity of daily living (IADL), an indirect 
evaluation of functional abilities necessary for independent 
living through caregiver interview [7]. Patients were classi-
fi ed in the category of  “ fi t ” patients if they had all of the fol-
lowing conditions: age    80, no limitations in ADL and IADL 
scores: ADL score 6 and IADL score 8, CIRS-G: no grade 
3 – 4 comorbidities (hematological comorbidities were not 
investigated) and fewer than fi ve grade 2 comorbidities. 
Patients were classifi ed as  “ unfi t ” if they had all of the fol-
lowing conditions: age    79, no limitations in ADL and IADL 
scores: ADL score 6 and IADL score 8, CIRS-G: no grade 3 – 4 
comorbidities and fewer than fi ve grade 2 comorbidities. In 
addition, patients aged    80 with an ADL score of 5 and/
or IADL score of 6 – 7, and/or CIRS-G: no grade 3 – 4 comor-
bidities and 5 – 8 grade 2 comorbidities were also classifi ed as 
 “ unfi t. ” All other patients who did not meet the criteria for fi t 
and unfi t patients were classifi ed as  “ frail ” [8] (Table I). Th e 
decision to treat a patient and the choice of type and inten-
sity of treatment were always left to the clinical judgement of 
the attending physician, according to the policy of the insti-
tution. Treatment with curative intent was defi ned as the use 
of a combination of an anthracycline-based chemotherapy 
(either liposomal or standard formulation), consisting of 
CHOP (cyclophosphamide, doxorubicin, vincristine, pred-
nisone) or CHOP-like regimens with rituximab, delivered at 
a relative dose intensity greater than 70% of the full dose as 
intent-to-treat. Patients considered unable to tolerate such 
treatment received other treatments, including radiation 
therapy only, low-dose chemotherapy without anthracy-
clines (cyclophosphamide, vincristine, prednisone [COP], 
low-dose COP), rituximab as a single agent, corticosteroids 
alone, oral monochemotherapy or anthracycline-based 
cycles at a relative dose intensity less than 70%, which were 
all defi ned as palliative therapy. 
 Table I. Defi nition of three geriatric risk categories according to age, comorbidities and functional abilities of 
daily living. 
CGA category
Fit Unfi t Frail
ADL 6 5 *    4 * 
IADL 8 6 – 7 *    5 * 
CIRS-G No comorbidity score 3 – 4 and 
   5 comorbidities score 2
No comorbidity score 3 – 4 
and 5 – 8 comorbidities 
score 2
   1 Comorbidity score 3 – 4 
or    8 comorbidities 
score 2
Age    80 fi t    80 unfi t
 ADL, activity of daily living; IADL, instrumental activity of daily living; CIRS-G, Cumulative Illness Rating Score for Geriatrics; 
CGA, comprehensive geriatric assessment. 
 * Number of residual functions. 
 Table II. Characteristics of patients classifi ed according to CGA * . 
CGA category All Fit Unfi t Frail  p -Value
No. of evaluable patients (%) 173 79 (46%) 28 (16%) 66 (38%)
M/F 91/82 52/27 13/15 26/40
Median age 77 74 79 81    0.0001
Ann Arbor stage III – IV (%)  †  57 57 58 58 NS
B symptoms (%)  ‡  32 25 24 37 NS
IPI risk class intermediate-high/high (%)  §  43 41 44 54 NS
 CGA, comprehensive geriatric assessment; IPI, International Prognostic Index; NS, not signifi cant. 
 * Data were available for 100% of patients in analysis except: 
  †  Stage: missing data in 3%. 
  ‡  B symptoms: missing data in 30%. 
  §  IPI: missing data in 6%. 
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 Th e purpose of the study was to evaluate the outcome of 
consecutive patients considering both the intensity of treat-
ment received and the results of CGA assessment. 
 Statistical analyses were performed using Prism software 
(GraphPad Software, La Jolla, CA). Th e overall survival (OS) 
time was computed from the initiation of therapy to the last 
visit that the patient was known to be alive or death from any 
cause, and was evaluated according to the Kaplan – Meier 
method [9]. Th e characteristics of the subgroups of patients 
divided according to the type of treatment received and CGA 
categorization were compared using the Fisher exact test, 
Student  t -test and Mann – Whitney statistics, as appropriate. 
Log-rank analysis was used to compare actuarial survival 
curves [10]. Th e multivariate analysis of survival was per-
formed using the Cox proportional hazard ratio (HR) [11] 
and 95% confi dence interval (CI), taking into account all 
variables that had been shown to be signifi cantly associated 
with survival in the univariate analysis. 
 Results 
 From September 2009 to August 2010, 177 patients aged more 
than 69 and aff ected by DLBCL were consecutively registered, 
and 173 of them had fully evaluable data to be considered for 
the present study. According to CGA, 79 (46%) patients were 
classifi ed as  “ fi t, ” 28 (16%) as  “ unfi t ” and 66 (38%) as  “ frail. ” 
Two fi t, one unfi t and one frail patient were lost to follow-up. 
Among unfi t patients, 50% were aged more than 79 without 
any other limitation, 15% had one or two limitations in IADL 
only, 23% in IADL and ADL, and 12% in IADL, with more than 
four comorbidities of grade 2. Among frail patients, 13% were 
aged more than 79 and unfi t, 15% had one or more comor-
bidities of grade 3, two patients had serious limitation only 
in IADL, while all other patients had limitations in two or 
more assessment scales. Th e main demographic and clini-
cal characteristics of this geriatric population are reported 
in Table II. Fit patients were signifi cantly younger compared 
with unfi t and frail patients ( p    0.0001), while no signifi cant 
diff erence concerning stage, B symptoms and International 
Prognostic Index (IPI) was observed. All but fi ve fi t patients 
(94%) received a curative treatment: one died before receiv-
ing any treatment, three patients with stage I disease received 
only radiation therapy and one patient with stage II disease 
received radiation and immunochemotherapy without antra-
cycline because of previous treatment for breast cancer. With 
a median follow-up of 24 months, their 2-year OS was sig-
nifi cantly better than the survival of non-fi t patients (84% vs. 
47%) ( p    0.0001). Among unfi t and frail patients the 2-year 
survival was 63% vs. 40%, respectively ( p    0.13) (Figure 1). 
 On the basis of clinical judgement, 17 unfi t patients 
(61%) and 18 frail patients (27%) received full-dose therapy 
with curative intent, and the remaining patients received 
palliation. Clinical characteristics of patients subdivided 
according to treatment actually received are shown in 
Table III and Supplementary Figure 1 to be found online at 
http://informahealthcare.com/doi/abs/10.3109/10428194.
2014.953142. Patients treated with curative intent were signifi -
cantly younger than patients receiving palliation ( p    0.001) 
and had a more advanced stage ( p    0.02), while no other 
signifi cant diff erences were recorded. 
 Considering patients treated with curative intent overall, 
the survival of fi t patients was signifi cantly better than the 
survival of non-fi t patients (88% vs. 56%) ( p    0.0001). 
 Within the single CGA categories, the 2-year OS of patients 
treated with curative or palliative intent was 88% vs. 25% 
( p    0.0001) in fi t, 75% vs. 45% ( p    0.32) in unfi t and 44% vs. 
39% ( p    0.75) in frail patients, respectively (Figure 2). 
 Th e rate of non-hematologic toxicity of grade    2 was not 
signifi cantly diff erent among patients treated, respectively, 
with curative or palliative intent (45% vs. 38%) ( p    0.3). Lym-
phoma was the main cause of death in both treatment groups. 
 At univariate analysis, age, IPI, CGA, ADL, IADL, CIRS-G, 
treatment approach (curative vs. palliative) and treatment 
dose-intensity (cut-off  70%) were signifi cantly associated 
 Figure 1.  Actuarial overall survival curves of elderly patients with DLBCL 
classifi ed as  “ fi t, ”  “ unfi t ” and  “ frail ” according to CGA, independent of 
treatment received. 
 Table III. Characteristics of unfi t and frail patients subdivided according to type of treatment actually received 
based on clinical judgement. 
Curative Palliative
Treatment Unfi t Frail Unfi t Frail  p -Value
No. of patients 17 18 11 48
Median age 78 78 83 82 0.001 * 
Ann Arbor stage III – IV 69% 78% 45% 49% 0.02 * 
B symptoms 33% 45% 10% 32% NS
IPI risk class intermediate-high/high 56 58 30 52 NS
ORR (CR   PR) 14 (82%) 13 (72%) 7 (64%) 25 (52%) NS
Relapse rate 2/14 4/13 2/7 5/25
Lymphoma death 60% 80% 80% 84% NS
Non-hematologic toxicity    2 40% 50% 40% 33% NS
 ORR, overall response rate; CR, complete remission; PR, partial remission; NS, not signifi cant. 
 * Comparison between all patients who received curative vs. palliative treatment. 
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 We used a modifi ed score originally proposed by Balducci 
and Extermann [3] that we validated in a small population 
of elderly patients with DLBCL [4] and that Spina  et  al . had 
already proposed as a modifi ed version [8]. Th e primary aim 
was to try to further divide the category of frail patients in 
order to modulate treatment intensity. A fully standardized 
geriatric assessment tool is not yet available. Th erefore, any 
choice in subdivision of the geriatric categories is some-
what arbitrary. However, the criteria we applied referred to 
validated rating scales and to previously published studies 
[4,15]. 
 Only short and rapid screening instruments can be widely 
accepted in oncology clinical practice [16,17]. Th is test is easy 
to perform, and does not require more than 15 min. Trained 
clinicians and nurses can work together according to their 
skills, assigning the comorbidity and ADL/IADL scores, 
respectively. Th e most important caution is to avoid defi ning 
a patient as frail because of a reduced performance status 
depending only on his advanced and symptomatic disease. 
Th is may carry a signifi cant risk of undertreating the patient. 
 More recently, great interest has been directed toward 
the prognostic role of nutritional parameters in the outcome 
of the geriatric population with cancer. Following observa-
tion of the close correlation between hypoalbuminemia 
and survival in elderly patients with DLBCL [18], sarcopenia 
was studied in this category of patients and was found to be 
a strong predictor of OS, but this approach is still not easily 
applicable in worldwide clinical practice [19]. 
 Th e results of this study, far from being a fi nal recommen-
dation to be adopted in clinical practice, represent a further 
step toward the development of a simple geriatric score able 
to defi ne diff erent categories of elderly patients with DLBCL 
suitable for diff erent treatment intensities. 
 According to the standard protocols for elderly patients 
with DLBCL [20], combination chemotherapy with CHOP 
or CHOP-like regimen with rituximab was chosen as the 
treatment strategy with curative intent. A relative dose inten-
sity of more than 70% of the standard dose was considered 
acceptable to maintain its therapeutic eff ect, as already 
demonstrated [21]. 
 Only patients classifi ed as fi t by CGA had a very satisfac-
tory clinical outcome using the intensive curative approach. 
Th e 2-year OS rate of 88% did not diff er from results achieved 
in younger patients with the same treatment [22,23]. More-
over, major toxic eff ects were limited, and only two patients 
died due to treatment-related toxicity. Th e benefi t of curative 
versus palliative treatment was lost in non-fi t patients, who 
had a poor outcome irrespective of the type of treatment 
received. Th e same results were obtained in a recent study 
by Marchesi  et  al ., who used a similar simplifi ed CGA [24]. 
In our study, frail patients more frequently had a worse IPI 
score and B symptoms compared with fi t patients, although 
the diff erence was not signifi cant; however, signifi cantly 
better survival of fi t compared to frail intensively treated 
patients was evident both in the subgroup of low and high 
IPI score, and in the subgroup of A and B stage, eliminating 
possible bias (data not shown). Compared to frail patients 
the outcome of unfi t patients was not signifi cantly diff er-
ent. However, there was a clear trend toward better survival, 
with OS. Within a multivariate analysis only IPI and CGA 
maintained their strong association with OS (Table IV). 
 Discussion 
 Th e results of our study confi rm that CGA is a strong inde-
pendent predictor of OS [12,13] and can be usefully applied 
to the treatment decision in elderly patients with DLBCL. 
 We adopted age 70 as the lower limit of clinical senescence, 
since the prevalence of age-related changes is represented by 
almost a plateau up to this age and increases sharply with 
older age [3,14]. 
 Figure 2. Actuarial overall survival curves of fi t (a), unfi t (b) and frail 
(c) elderly patients with DLBCL, each group subdivided according to 
treatment received (curative vs. palliative). 
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especially in the subgroup treated with curative intent. 
While the small number of unfi t patients identifi ed by CGA 
criteria may have limited the statistical power of the study, 
these results suggest that eff orts in modulating the treatment 
intensity in this intermediate category of patients might be 
worthwhile in order to further improve their outcome, and 
to reduce the number of elderly patients who might ben-
efi t from palliative care only. Modulation of chemotherapy 
according to CGA has already been proposed by diff erent 
authors [8,13]. Spina  et  al . obtained interesting results by 
adjusting the single chemotherapeutic agent according to 
comorbidities and total doses according to ADL/IADL. An 
attenuated immunochemotherapy regimen (rituximab-
miniCHOP) was used by a French group in elderly patients 
aged over 80 years without any other CGA parameter selec-
tion, obtaining a good compromise between effi  cacy and 
safety [18]. Th e combination of a lower dose of immuno-
chemotherapy with a biological drug could also be a valid 
alternative to be tested in a clinical trial. 
 In conclusion, the CGA used in our study proved to be an 
effi  cient method to identify elderly patients with DLBCL who 
can benefi t from a curative approach with anthracycline-
containing immuno-chemotherapy. It further suggests the 
potential usefulness of identifying diff erent risk groups in the 
category of non-fi t patients, by showing that a proportion of 
unfi t patients exist who could obtain signifi cant benefi t when 
treated with curative intent. Th erefore, new risk-adapted 
strategies of treatment through modulated-intensity pro-
grams could reduce the diff erence of survival between fi t 
and unfi t patients, and clinical trials in this setting should be 
planned. Palliation seems the best choice for frail patients, 
and improvement of supportive care is the only eff ort that 
might be proposed in this category of patients. 
 Potential confl ict of interest:  Disclosure forms provided 
by the authors are available with the full text of this article at 
www.informahealthcare.com/lal. 
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CGA 5.61 (2.95 – 10.64) 0.0001 3.69 (1.09 – 12.51) 0.03
ADL (   5 vs. 6) 0.3 (0.17 – 0.51) 0.0001
IADL (   6 vs.    7) 0.24 (0.14 – 0.41) 0.0001
CIRS-G grade 2 (   5 vs.    5) 2.89 (1.04 – 8.03) 0.04
CIRS-G grade 3 – 4 (0 vs.    1) 2.14 (1.22 – 3.73) 0.007
Curative vs. palliative treatment approach 0.27 (0.16 – 0.46) 0.0001
Treatment dose (   70% vs.    70%) 0.38 (0.17 – 0.86) 0.02
 IPI, International Prognostic Index; CGA, comprehensive geriatric assessment; ADL, activity of daily living; IADL, instrumental 
activity of daily living; CIRS-G, Cumulative Illness Rating Score for Geriatrics; HR, hazard ratio; CI, confi dence interval. 
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